SynthesisPharmacoEconomics - open2023
Humanistic and Economic Burden of IgA Nephropathy: Systematic Literature Reviews and Narrative Synthesis.
Synthesis in PharmacoEconomics - open, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 2 syntheses or guidelines pooled it, 10 citations in OpenAlex.
- Efficacy of SGLT2 inhibitors in preventing end-stage kidney disease in patients with IgA nephropathy: a scoping review.Frontiers in medicine · 2026Pooled it
- A Systematic Literature Review on the Burden of Disease for Patients With Moderate to Severe Acute Ischemic Stroke.Medicine · 2025Pooled it
- Health Care Resource Utilization and Associated Costs Across Proteinuria and Declining Kidney Function in Patients With IgA Nephropathy: A Retrospective Study in Three European Countries.Kidney medicine · 2026Article
- External validation of the international IgA nephropathy prediction tool in a Thai cohort.Frontiers in medicine · 2026Article
- Clinical Characteristics as Predictors of Healthcare Resource Utilization in Immunoglobulin A Nephropathy: A Retrospective Database Study.Journal of health economics and outcomes research · 2026Article
- The humanistic burden of immunoglobulin A nephropathy on patients and care-partners in the United States.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Article
- Real-world challenges associated with the use of four common systemic glucocorticoids in a United States IgAN cohort.Frontiers in nephrology · 2025Article
- Risk prediction for gastrointestinal bleeding in pediatric Henoch-Schönlein purpura using an interpretable transformer model.Frontiers in physiology · 2025Article
- Healthcare of patients with immunoglobulin A nephropathy through a retrospective observational study of Italian administrative data.Global & regional health technology assessmentArticle
- Health Care Resource Utilization and Productivity Impairment in Adults with Immunoglobulin A Nephropathy: A Real-World, Observational, Global Analysis.Glomerular diseasesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunoglobulin A nephropathy (IgAN) is a progressive inflammatory kidney disease requiring long-term treatment to reduce the risk of progression to kidney failure. Here, we present two systematic literature reviews (SLRs) to identify and summarize literature reporting the humanistic and economic burden of IgAN.
methodsElectronic literature databases (Ovid Embase, PubMed, and Cochrane) were searched for relevant literature on 29 November 2021, supplemented with gray literature searches. Studies reporting any health-related quality of life (HRQoL) or health state utility outcomes in IgAN patients were included in the humanistic impact SLR, and studies reporting the costs and healthcare resource utilization associated with or economic models of IgAN disease management were included in the economic burden SLR. Narrative synthesis was used to discuss the heterogeneous studies included in the SLRs. Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Cochrane guidelines were followed, and all included studies were assessed for risk of bias using the Center for Evidence-Based Management tool for Critical Appraisal of a Survey or the Drummond Checklist.
resultsA total of 876 and 1122 references were identified from electronic and gray literature searches for humanistic and economic burden, respectively. Three studies reporting humanistic impact and five studies reporting economic burden met criteria for inclusion in these SLRs. The included humanistic studies reported patient preferences in the USA and China, HRQoL for patients with IgAN in Poland, and impact of exercise on HRQoL for patients with IgAN in China. The five economic studies reported costs of IgAN treatment in Canada, Italy, and China, along with two economic models from Japan. DISCUSSION: Current literature suggests IgAN is associated with substantial humanistic and economic burdens. However, these SLRs demonstrate the paucity of research conducted to specifically describe the humanistic or economic burden of IgAN and highlight the need for further research.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.